Prevalence of nonclassic adrenal hyperplasia (NCAH) in hyperandrogenic women

References

• Knochenhauer E S, Key T J, Kahsar-Miller M, Waggoner W, Boots L R, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078–3082
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Kouli C R, Bergiele A T, Filandra F A, Tsianateli T C, Spina G G, Zapanti E D, Bartzis M I. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999; 84: 4006–4011
   PubMed Web of Science ®Google Scholar
• Asuncion M, Calvo R M, San Millan J L, Sancho J, Avila S, Escobar-Morreale H F. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85: 2434–2438
   PubMed Web of Science ®Google Scholar
• Azziz R, Nestler J E, Dewailly D. Androgen Excess Disorders in Women. Lippincott-Raven 1997; 177
   Google Scholar
• Speiser P W, Dupont B, Rubinstein P, Piazza A, Kastelan A, New M I. High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet 1985; 37: 650–667
   PubMed Web of Science ®Google Scholar
• Azziz R, Dewailly D, Owerbach D. Non-classic adrenal hyperplasia: current concepts. J Clin Endocrinol Metab 1994; 78: 810–815
   PubMed Web of Science ®Google Scholar
• Morel Y, David M, Forest M G, Bétuel H, Hauptman G, Andre J, Bertrand J, Miller W L. Gene conversions and rearrangements cause discordance between inheritance of forms of 21-hydroxylase deficiency and HLA types. J Clin Endocrinol Metab 1989; 68: 592–598
   PubMedGoogle Scholar
• Moran C, Azziz R. 21-hydroxylase-deficient nonclassic adrenal hyperplasia: the great pretender. Semin Reprod Med 2003; 21(3)295–300
   PubMedGoogle Scholar
• Romaguera J, Moran C, Diaz-Montes T P, Hines G A, Cruz R I, Azziz R. Prevalence of 21-hydroxylase-deficient nonclassic adrenal hyperplasia and insulin resistance among hirsute women from Puerto Rico. Fertil Steril 2000; 74(1)59–62
   PubMedGoogle Scholar
• O'Driscoll J B, Mamtora H, Higginson J, Pollock A, Kane J, Anderson D C. A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia. Clin Endocrinol (Oxf) 1994; 41: 231–236
   PubMed Web of Science ®Google Scholar
• Arnaout M A. Late-onset congenital adrenal hyperplasia in women with hirsutism. Eur J Clin Invest 1992; 22(10)651–658
   PubMedGoogle Scholar
• Azziz R, Sanchez L A, Knochenhauer E S, Moran C, Lazenby J, Stephens K C, Taylor K, Boots L R. Androgen Excess in Women: Experience with Over 1000 Consecutive Patients. J Clin Endocrinol Metab 2004; 89(2)453–462
   PubMed Web of Science ®Google Scholar
• Carmina E, Rosato F, Janni A, Rizzo M, Longo R A. Relative Prevalence of Different Androgen Excess Disorders in 950 Women Referred because of Clinical Hyperandrogenism. Journal of Clinical Endocrinology and Metabolism 2006; 91: 2–6
   PubMed Web of Science ®Google Scholar
• Moran C, Azziz R, Carmina E, Dewailly D, Fruzzetti F, Ibanez L, Knochenhauer E S, Marcondes J A, Mendonca B B, Pignatelli D, Pugeat M, Rohmer V, Speiser P W, Witchel S F. 21-Hydroxylase- deficient nonclassic adrenal hyperplasia is a progressive disorder: A multicenter study. Am J Obstet Gynecol 2000; 183: 1468–1474
   PubMed Web of Science ®Google Scholar
• Spritzer P, Billaud L, Thalabard JCh, Birman P, Mowszowicz I, Raux-Demay M C, Kuttenn F, Mauvais-Jarvis P. Cyproterone Acetate versus Hydrocortisone Treatment in Late-Onset Adrenal Hyperplasia. J Clin Endocrinol Metab 1990; 70: 642–666
   PubMed Web of Science ®Google Scholar
• Carmina E, Lobo R A. Ovarian supression reduces clinical and endocrine expression of late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Fertil Steril 1994; 62(4)738–743
   PubMedGoogle Scholar
• Ciampelli M, Fulghesu A M, Cucinelli F, Pavone V, Ronsisvalle E, Guido M, Caruso A, Lanzone A. Impact of of insulin and bodmass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism 1999; 48: 167–172
   PubMed Web of Science ®Google Scholar
• Cibula D, Hill M, Fanta M, Sindelka G, Zivny J. Does obesity diminish the positive effect of oral contraceptive treatment on hyperandrogenism in women with polycystic ovarian syndrome?. Hum Reprod 2001; 16: 940–944
   PubMedGoogle Scholar
• Azziz R, Hincapie L A, Knochenhauer E S, Dewailly D, Fox L, Boots L R. Screening for 21-hydroxylase deficient non-classic adrenal hyperplasia among hyperandrogenic women: a prospective study. Fertil Steril 1999; 72: 915–925
   PubMed Web of Science ®Google Scholar